AstraZeneca got a closer look at CSPC’s drug research capabilities last year. Last October, the pharma giant paid $100 million up front to license a preclinical CSPC drug in development for the ...

AstraZeneca PLC (NASDAQ:AZN) is one of the 11 Best Strong Buy Stocks to Invest in Now. On June 13, AstraZeneca PLC ...

AstraZeneca has entered a strategic research collaboration with China's CSPC Pharmaceutical Group, aiming to accelerate the ...

AstraZeneca has returned to recent licensing partner CSPC Pharmaceutical with $110 million in upfront cash to start work on finding new oral drugs for a range of chronic diseases.. The Friday ...

AstraZeneca (AZN) on Friday announced a strategic research collaboration with China-based CSPC Pharmaceuticals Group to advance the development of oral drug candidates with the potential to treat ...

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

AI-Powered Collaboration: AstraZeneca and CSPC partner to develop novel oral therapies for chronic and immunological diseases affecting over two billion people globally. High-Value Deal Structure: ...

AstraZeneca said on Monday it would pay up to $1.92 billion to CSPC Pharmaceutical Group Ltd in an exclusive licence agreement to boost the Anglo-Swedish drugmaker's cardiovascular pipeline.

AstraZeneca has paid CSPC Pharmaceutical Group $100 million for a preclinical cardiovascular disease drug. The deal, which covers a potential rival to an Eli Lilly prospect, ...

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic ...